# ENB003

Source: https://onco.cc/drugs/enb003/  
OnCo record `enb003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.

## Summary

ENB003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ENB Therapeutics, Inc, in melanoma. Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: ENB003
- Modality: Small-molecule antagonist
- Mechanism: Described in the registry record as a nb003 is selective endothelin b receptor antagonist; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of ENB003: https://clinicaltrials.gov/search?intr=ENB003

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- trials: [ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors](https://onco.cc/trials/nct04205227/)

---
JSON: https://onco.cc/api/v1/entities/enb003.json